Procarbazine Hydrochloride

盐酸丙卡巴肼

Report date: 2022/04/22 09:33:11
NME

Base Information

Drug NameProcarbazine Hydrochloride
Drug Alias Name甲基苄肼盐酸盐procarbazinaprocarbazine盐酸异丙胺酰苄肼甲苄肼 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsCNS Embryonal TumorBrain NeoplasmsHodgkin Disease
Global Approved IndicationsBrain NeoplasmsHodgkin Disease
Approved Indications in ChinaHodgkin Disease
Original Approved Country/TerritoryUnited States
Original Approved Date1969/07/22
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSigma-Tau Spa
China Registration ClassN/A

Develop Information

Active CompaniesLeadiant Biosciences IncZhaoke Pharmaceutical (Hefei) Co Ltd
Inactive CompaniesHaupt Pharma Amareg GmbhNational Cancer InstituteSigma-Tau Pharmaceutical Group
Active IndicationsBrain NeoplasmsHodgkin Disease
Inactive IndicationsCNS Embryonal Tumor

Other Information

ATC CodeL01XB01
Related LinksWikipediaDrugBankKEGG